4Moving Biotech (4MB), a clinical-stage biotechnology company spun out of 4P-Pharma, said it has closed a €12 million financing to advance its lead disease-modifying osteoarthritis drug (DMOAD) program for knee osteoarthritis, a condition the company says represents a major unmet medical need.
The Lille- and Paris-based company said the financing was completed through a “structured and coordinated” process and was secured from private investors and family offices. The capital was raised at the subsidiary level in 4MB and includes a mix of equity and loans, which the company described as a flexible structure aligned with long-term value creation.
4MB said the new funding extends its financial runway toward a Phase 2a proof-of-concept inflection point. The company framed the close as a continuation of prior non-dilutive support, including a €7.6 million France 2030 i-Démo grant announced last year, and pointed to a recent transatlantic extension of its INFLAM-MOTION Phase 2a clinical study to the U.S.
Founded in 2020, 4MB said it has now received roughly €30 million in total funding to date, combining private financing and public, non-dilutive support. The company also tied the raise to 4P-Pharma’s broader platform approach, which it characterizes as a start-up studio model in which subsidiaries independently define and execute their development paths.
In the near term, 4MB said it will focus on executing its clinical strategy, preparing for future regulatory interactions, and working to facilitate patient access to its molecule.
KEY QUOTES
“With this closing in place, we are well equipped to reach the next value creation milestone by delivering robust Phase 2a data, reaching a proof-of-concept inflection point, and creating strategic optionality for subsequent stages of development to address the needs of the 374 million patients suffering from osteoarthritis worldwide.”
Luc Boblet, CEO, 4Moving Biotech
“The arrival of new investors in 4MB reflects the strength and coherence of the 4P-Pharma group’s platform, built on disciplined capital allocation and scientific rigor. By enabling our subsidiaries to independently define and execute their own trajectories, 4P-Pharma demonstrates the relevance of its start-up studio model.”
Revital Rattenbach, CEO, 4P-Pharma; Co-Founder, 4Moving Biotech
